Biochemical and biophysical analysis of five disease-associated human adenylosuccinate lyase mutants.

Lushanti De Zoysa Ariyananda, Peychii Lee, Christina Antonopoulos, Roberta F Colman
Author Information
  1. Lushanti De Zoysa Ariyananda: Department of Chemistry and Biochemistry, University of Delaware, Newark, Delaware 19716, USA.

Abstract

Adenylosuccinate lyase (ASL), a catalyst of key reactions in purine biosynthesis, is normally a homotetramer in which three subunits contribute to each of four active sites. Human ASL deficiency is an inherited metabolic disease associated with autism and mental retardation. We have characterized five disease-associated ASL mutants: R194C and K246E are located at subunit interfaces, L311V is in the central helical region away from the active site, and R396C and R396H are at the entrance to the active site. The V(max) (at 25 degrees C) for R194C is comparable to that of WT, while those of L311V, R396C, R396H, and K246E are considerably reduced and affinity for adenylosuccinate is retained. The mutant enzymes have decreased positive cooperativity as compared to WT. K246E exists mainly as dimer or monomer, accounting for its negligible activity, whereas the other mutant enzymes are similar to WT in the predominance of tetramer. At 37 degrees C, the specific activity of WT and these mutant enzymes slowly decreases 30-40% with time and reaches a limiting specific activity without changing significantly the amount of tetramer. Mutant R194C is unique in being rapidly inactivated at the harsher temperature of 60 degrees C, indicating that it is the least stable enzyme in vitro. Conformational changes in the mutant enzymes are evident from protein fluorescence intensity at 25 degrees C and after incubation at 37 degrees C, which correlates with the loss of enzymatic activity. Thus, these disease-associated single mutations can yield enzyme with reduced activity either by affecting the active site or by perturbing the enzyme's structure and/or native conformation which are required for catalytic function.

References

  1. Biochemistry. 2003 Feb 25;42(7):1831-41 [PMID: 12590570]
  2. Arch Biochem Biophys. 1981 Oct 15;211(2):564-74 [PMID: 7197899]
  3. Biophys J. 2001 May;80(5):2093-109 [PMID: 11325713]
  4. Biochem J. 1998 Jul 15;333 ( Pt 2):327-34 [PMID: 9657972]
  5. J Biol Chem. 1993 Nov 25;268(33):24868-72 [PMID: 7693707]
  6. Biochemistry. 1998 Jul 14;37(28):9976-82 [PMID: 9665702]
  7. Eur J Pediatr. 1988 Nov;148(2):126-31 [PMID: 3234432]
  8. Biochim Biophys Acta. 2009 Apr;1794(4):642-54 [PMID: 19111634]
  9. Biochemistry. 2006 Jun 20;45(24):7429-33 [PMID: 16768438]
  10. J Pediatr. 2007 Jan;150(1):57-61.e2 [PMID: 17188615]
  11. Biophys Chem. 2006 Aug 1;122(3):157-83 [PMID: 16690201]
  12. Bioinformatics. 2007 Jan 15;23(2):e99-103 [PMID: 17237112]
  13. Nature. 1970 Aug 15;227(5259):680-5 [PMID: 5432063]
  14. Lancet. 1984 Nov 10;2(8411):1058-61 [PMID: 6150139]
  15. Hum Mutat. 1999;13(3):197-202 [PMID: 10090474]
  16. Anal Biochem. 1976 May 7;72:248-54 [PMID: 942051]
  17. Biochim Biophys Acta. 2008 Nov;1784(11):1493-500 [PMID: 18620084]
  18. Biochemistry. 2002 Feb 19;41(7):2217-26 [PMID: 11841213]
  19. Anal Biochem. 1979 Apr 1;94(1):75-81 [PMID: 37780]
  20. Protein Sci. 2008 Jul;17(7):1162-74 [PMID: 18469177]
  21. J Biol Chem. 1968 Feb 10;243(3):644-50 [PMID: 5637715]
  22. Science. 1985 Jul 5;229(4708):23-8 [PMID: 3892686]
  23. Mol Genet Metab. 2006 Sep-Oct;89(1-2):19-31 [PMID: 16839792]
  24. Biophys J. 1997 Jul;73(1):31-7 [PMID: 9199768]
  25. Biochemistry. 2006 May 16;45(19):5974-84 [PMID: 16681369]
  26. Neuropediatrics. 2002 Aug;33(4):186-9 [PMID: 12368987]
  27. Biochemistry. 1984 Oct 23;23(22):5168-75 [PMID: 6509019]
  28. Biochemistry. 2008 Dec 2;47(48):12844-52 [PMID: 18991402]
  29. Protein Expr Purif. 2007 Feb;51(2):227-34 [PMID: 16973378]
  30. J Chromatogr A. 2002 Nov 29;978(1-2):71-9 [PMID: 12458946]
  31. J Biol Chem. 1972 Jan 10;247(1):162-9 [PMID: 5017762]

Grants

  1. R01 DK060504/NIDDK NIH HHS
  2. P20 RR016472/NCRR NIH HHS
  3. R01 DK060504-03/NIDDK NIH HHS
  4. AS2200/Autism Speaks
  5. 2P20 RR016472/NCRR NIH HHS
  6. R01-DK60504/NIDDK NIH HHS

MeSH Term

Adenylosuccinate Lyase
Autistic Disorder
Circular Dichroism
Crystallography, X-Ray
Humans
Intellectual Disability
Kinetics
Models, Molecular
Molecular Weight
Mutagenesis, Site-Directed
Mutation
Protein Structure, Secondary
Spectrometry, Fluorescence
Temperature

Chemicals

Adenylosuccinate Lyase

Word Cloud

Created with Highcharts 10.0.0degreesCactivityactiveWTmutantenzymesASLdisease-associatedR194CK246EsitelyasefiveL311VR396CR396H25reducedadenylosuccinatetetramer37specificenzymeAdenylosuccinatecatalystkeyreactionspurinebiosynthesisnormallyhomotetramerthreesubunitscontributefoursitesHumandeficiencyinheritedmetabolicdiseaseassociatedautismmentalretardationcharacterizedmutants:locatedsubunitinterfacescentralhelicalregionawayentranceVmaxcomparableconsiderablyaffinityretaineddecreasedpositivecooperativitycomparedexistsmainlydimermonomeraccountingnegligiblewhereassimilarpredominanceslowlydecreases30-40%timereacheslimitingwithoutchangingsignificantlyamountMutantuniquerapidlyinactivatedharshertemperature60indicatingleaststablevitroConformationalchangesevidentproteinfluorescenceintensityincubationcorrelateslossenzymaticThussinglemutationscanyieldeitheraffectingperturbingenzyme'sstructureand/ornativeconformationrequiredcatalyticfunctionBiochemicalbiophysicalanalysishumanmutants

Similar Articles

Cited By